- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02583425
Pilot Study of DFN-11 Injection in Medication Overuse Headache
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Missouri
-
Springfield, Missouri, United States, 65807
- Clinvest
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of medication overuse headache within the past year in the following categories
- Diagnosis of migraine, with or without aura for at least 12 months
- Experience an average of > 10 headache days per month for the past 12 months
Females must:
i. be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and willing to continue throughout the study, or ii. be surgically sterile, (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or iii. be postmenopausal (spontaneous amenorrhea for at least 1 year)
- Females of child-bearing potential must have a negative urine pregnancy test at all visits.
- Able and willing to read and comprehend written instructions and complete the electronic diary.
- Must have internet access to complete daily headache diary.
Exclusion Criteria:
- Current use of medication for headache/migraine prophylaxis that has not been stable for 30 days prior to screening. Stable is defined as no recent dosing change within 30 days of screening.
- Hemiplegic or basilar migraine
- History, symptoms or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes
- Uncontrolled hypertension (screening systolic/diastolic blood pressure > 140/90 mmHg in 2 out of 3 readings)
- Clinically significant hepatic impairment
- History of epilepsy or conditions associated, which in the opinion of the Investigator, increase the likelihood of present day seizure
- History (within 2 years) of drug or alcohol abuse as defined by DSM-IV-TR criteria
- Systemic disease, which in the opinion of the Investigator, would contraindicate participation
- History of a neurological or psychiatric condition, which in the opinion of the Investigator would contraindicate participation
- Pregnant or lactating women
- Have taken any investigational medication within 30 days before screening, or are scheduled to receive an investigational drug
- Subjects with a positive urine drug screen for recreational drugs or marijuana (whether legal or not) or for prescription drugs not explained by stated concomitant medications
- Clinical laboratory or electrocardiogram (ECG) abnormality that in the opinion of the Investigator would endanger the subject or interfere with the study conduct. If the results of the clinical laboratory or ECG are outside of normal reference range the subject may still be enrolled but only if these findings are determined to be not clinically significant by the Investigator. This determination must be recorded in the subject's source document prior to enrolment.
- Fridericia's corrected QT (QTcF) interval greater than 450 msec
- Severe renal impairment (creatinine > 2 mg/dl)
- Serum total bilirubin > 2.0 mg/dL
- Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase > 2.5 times the upper limit of normal
- Subjects with uncontrolled diabetes mellitus, or a glycosylated hemoglobin (HbA1c) > 7.0%, or with diabetes mellitus requiring insulin
- Subjects who in the opinion of the investigator experience rebound headache from caffeine usage
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DFN-11
DFN-11 Injection upon occurrence of migraine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Number of Headache Hours in the Baseline Period (28 Days of Subjects Using Their Usual Medication for Headaches) and in the Treatment Period (28 Days of Subjects Using DFN-11 for Headaches)
Time Frame: 28 days Baseline period and 28 days of Treatment period (Total 56 days)
|
28 days Baseline period and 28 days of Treatment period (Total 56 days)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Number of Acute Headache Medication Doses in the Baseline Period (28 Days of Subjects Using Their Usual Medication for Headaches) and in the Treatment Period (28 Days of Subjects Using DFN-11 for Headaches)
Time Frame: 28 days Baseline period and 28 days of Treatment period (Total 56 days)
|
28 days Baseline period and 28 days of Treatment period (Total 56 days)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DFN-11-CD-007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Medication Overuse Headache
-
Hospital of South West JutlandCompletedMedication-overuse Headache | Secondary Headache Disorders
-
Danish Headache CenterCompletedMedication-overuse HeadacheDenmark
-
Wei DaiInternational Headache SocietyRecruitingMigraine Disorders | Medication-overuse HeadacheChina
-
University Hospital, AkershusUniversity of OsloCompletedChronic Headache | Medication-overuse HeadacheNorway
-
University of CalgaryAlberta Health servicesCompletedMedication Overuse Headache | Analgesic Overuse HeadacheCanada
-
H. Lundbeck A/SRecruitingMigraine | Medication Overuse HeadacheSpain, Italy, United States, Denmark, France, Netherlands, Australia, Georgia, Germany, Norway, Sweden
-
AmgenCompletedMigraine HeadacheUnited States, Austria, Australia, Czechia, Finland, France, Hungary, Italy, Poland, Portugal, Spain, United Kingdom
-
Diskapi Teaching and Research HospitalActive, not recruitingMedication Overuse HeadacheTurkey
-
Norwegian University of Science and TechnologyCompleted
-
IRCCS National Neurological Institute "C. Mondino...CompletedMedication Overuse Headache
Clinical Trials on DFN-11 Injection
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompletedRapidly Escalating MigraineUnited States
-
Dr. Reddy's Laboratories LimitedCompleted
-
Peking Union Medical College HospitalRecruitingProstate Cancer MetastaticChina
-
Peking Union Medical College HospitalRecruiting
-
Beijing Northland Biotech. Co., Ltd.CompletedChemotherapy-induced ThrombocytopeniaChina
-
Anhui Provincial HospitalRecruitingProstate Cancer | PET/CTChina
-
Beijing Tiantan HospitalJiangsu Wangao Pharmaceutical Co. ltdRecruiting